Phase 2 Mesothelioma Trial, Recruiting NCT07121374 Sponsor: University Hospital, Antwerp Condition: Mesothelioma
Back to Mesothelioma

Phase 2 Mesothelioma Trial, Recruiting

NCT07121374
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are able to give written consent and are willing to follow the study procedures
  • You have been diagnosed with a specific type of mesothelioma (epithelioid pleural mesothelioma) confirmed by a tissue test, at a stage that is currently considered inoperable (not suitable for surgery) but may become operable after initial treatment
  • You are 18 years of age or older
  • You are in good general health and able to carry out daily activities with little or no limitation (as measured by a standard health scale)
  • You are healthy enough to receive chemotherapy, immunotherapy, and surgery based on your doctor's assessment
  • If you are a woman who could become pregnant, you must use effective contraception during the trial; if you are a man, you must use a condom to prevent pregnancy in a female partner

Who may not be able to join:

  • Your mesothelioma is either at an early stage already suitable for surgery, or at a very advanced stage where surgery would not become possible even after initial treatment
  • You have cancer that has spread to the other side of the chest or to other parts of the body (detected by a PET scan or CT scan)
  • You are not well enough to receive chemotherapy, immunotherapy, or chest surgery — this includes people with active autoimmune diseases, a history of spleen removal, an active infection requiring antibiotics, long-term infections such as HIV or hepatitis B or C, or serious heart disease
  • You have a known allergy or serious reaction to any of the medications used in this trial (including platinum-based drugs, pemetrexed, ipilimumab, or nivolumab)
  • You have another active cancer, other than a common type of skin cancer (basal cell carcinoma) or early-stage cervical changes, or you have cancer that has spread to the brain
  • You have previously received chemotherapy, immunotherapy, radiation to the chest, or surgery (other than a keyhole procedure to diagnose your condition)
  • You have significant difficulties with mental health, personal, family, social, or practical circumstances that your doctor feels could make it hard to follow the study requirements (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +3238214361

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
University Hospital, Antwerp
Registry
ClinicalTrials.gov
Start date
22 July 2025
Est. completion
1 June 2028

Where this trial is recruiting

🇧🇪 Belgium

Primary endpoints

To assess the percentage of successful completion of a neoadjuvant double chemotherapy / double immunotherapy regimen followed by surgery in a selected group of T2-T3 (according to TNM 9) patients with pleural mesothelioma.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov